Mersana Therapeutics is a clinical-stage biopharmaceutical company using its differentiated and proprietary ADC platforms to develop highly targeted drugs with increased tolerability and expanded opportunities to deliver meaningful clinical benefit to patients. Mersanaâs lead product candidate, XMT-1536, is in a Phase 1 clinical trial in patients with tumors expressing NaPi2b, including ovarian cancer, NSCLC and other cancers. In addition, multiple partners are using Mersanaâs platform to advance their ADC pipelines. Source
No articles found.
MyoKardia is a clinical-stage biopharmaceutical company pioneering a precision med...
MyoKardia is a clinical-stage biopharmaceutical...
Abiomed (NASDAQ: ABMD) is a leading provider of medical devices that provide circu...
Abiomed (NASDAQ: ABMD) is a leading provider of...
Pulmatrix is a clinical stage biopharmaceutical company developing innovative inha...
Pulmatrix is a clinical stage biopharmaceutical...
Sonoma Pharmaceuticals is a specialty pharmaceutical company that develops and mar...
Sonoma Pharmaceuticals is a specialty pharmaceu...
Join the National Investor Network and get the latest information with your interests in mind.